The Duke-Margolis white paper highlights the critical issue of drug shortages in the American healthcare system and suggests the creation of a Prevent Drug Shortages (PDS) Initiative to address it. The paper identifies manufacturing quality issues and pricing dynamics as leading causes of these shortages, particularly affecting generic drug manufacturers. It also acknowledges the API Innovation Center’s role in encouraging innovative manufacturing technologies to ensure a reliable domestic supply of Active Pharmaceutical Ingredients (APIs) for essential medicines, emphasizing its commitment to pharmaceutical quality and addressing drug shortages in the United States.

Read the Duke Margolis White Paper